Advertisement

Pulmatrix Inc. in Lexington is collaborating with the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) in a deal worth up to $1.4 million to bring the biotech’s inhaled drug candidate, PUR118, to treat cystic fibrosis, through clinical trials.

Advertisement
Advertisement